X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (501) 501
Publication (49) 49
Book Review (4) 4
Book Chapter (2) 2
Conference Proceeding (2) 2
Book / eBook (1) 1
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (338) 338
animals (264) 264
male (218) 218
index medicus (166) 166
female (162) 162
heparitin sulfate - metabolism (138) 138
heparitin sulfate - administration & dosage (111) 111
mice (109) 109
heparitin sulfate - therapeutic use (102) 102
heparin - adverse effects (95) 95
heparan sulfate (90) 90
rats (86) 86
heparin (84) 84
chondroitin sulfates - therapeutic use (83) 83
dermatan sulfate - therapeutic use (83) 83
middle aged (82) 82
thrombocytopenia - chemically induced (80) 80
adult (76) 76
aged (73) 73
chondroitin sulfates - administration & dosage (72) 72
dermatan sulfate - administration & dosage (71) 71
anticoagulants - therapeutic use (70) 70
heparitin sulfate - pharmacology (68) 68
glycosaminoglycans (67) 67
drug combinations (65) 65
anticoagulants - adverse effects (62) 62
anticoagulants - administration & dosage (60) 60
biochemistry & molecular biology (55) 55
hematology (53) 53
sulfates (52) 52
proteoglycans (48) 48
heparitin sulfate (47) 47
heparitin sulfate - chemistry (44) 44
peripheral vascular disease (44) 44
dermatan sulfate (43) 43
heparin - administration & dosage (42) 42
chondroitin sulfates (41) 41
glycosaminoglycans - metabolism (41) 41
thrombosis (41) 41
cell biology (39) 39
proteins (39) 39
heparin-induced thrombocytopenia (38) 38
medicine, research & experimental (38) 38
thrombocytopenia - drug therapy (38) 38
heparin - pharmacology (37) 37
surgery (37) 37
anticoagulants (36) 36
dose-response relationship, drug (36) 36
heparitin sulfate - adverse effects (36) 36
research (35) 35
sulfate (35) 35
time factors (35) 35
binding (34) 34
research article (34) 34
chondroitin sulfates - adverse effects (33) 33
dermatan sulfate - adverse effects (33) 33
expression (33) 33
heparitin sulfate - biosynthesis (32) 32
medicine (32) 32
pharmacology & pharmacy (32) 32
disease models, animal (31) 31
health aspects (31) 31
heparan sulfate proteoglycans (31) 31
treatment outcome (30) 30
danaparoid (29) 29
heparin - therapeutic use (29) 29
molecular-weight heparin (29) 29
cells, cultured (28) 28
mice, inbred c57bl (28) 28
respiratory system (28) 28
aged, 80 and over (27) 27
injections, intravenous (27) 27
platelet count (27) 27
glycosaminoglycans - administration & dosage (26) 26
multidisciplinary sciences (26) 26
physiological aspects (26) 26
anticoagulants - pharmacology (25) 25
cells (25) 25
enzymes (25) 25
glycosaminoglycans - pharmacology (25) 25
immunohistochemistry (25) 25
inhibition (24) 24
org-10172 (24) 24
analysis (23) 23
antibodies (23) 23
extracellular matrix (23) 23
fibroblast-growth-factor (23) 23
liver - metabolism (23) 23
molecular weight (23) 23
rats, sprague-dawley (23) 23
thrombocytopenia (23) 23
angiogenesis (22) 22
biology (22) 22
extracellular-matrix (22) 22
genetics & heredity (22) 22
heparinoids - therapeutic use (22) 22
inflammation (21) 21
injections, subcutaneous (21) 21
protein binding (21) 21
rats, wistar (21) 21
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (461) 461
German (17) 17
French (9) 9
Italian (6) 6
Japanese (4) 4
Czech (1) 1
Polish (1) 1
Russian (1) 1
Serbian (1) 1
Spanish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Chest, ISSN 0012-3692, 2012, Volume 141, Issue 2, pp. e24S - e43S
This article describes the pharmacology of approved parenteral anticoagulants. These include the indirect anticoagulants, unfractionated heparin (UFH),... 
RESPIRATORY SYSTEM | CRITICAL CARE MEDICINE | Heparitin Sulfate - adverse effects | United States | Humans | Thrombin - antagonists & inhibitors | Heparin - administration & dosage | Heparin, Low-Molecular-Weight - adverse effects | Recombinant Proteins - adverse effects | Heparin - adverse effects | Hirudins - administration & dosage | Dose-Response Relationship, Drug | Pipecolic Acids - administration & dosage | Chondroitin Sulfates - adverse effects | Societies, Medical | Pipecolic Acids - adverse effects | Heparitin Sulfate - administration & dosage | Polysaccharides - administration & dosage | Thrombosis - blood | Thrombosis - prevention & control | Dermatan Sulfate - administration & dosage | Dermatan Sulfate - adverse effects | Peptide Fragments - administration & dosage | Polysaccharides - adverse effects | Evidence-Based Medicine | Recombinant Proteins - administration & dosage | Antithrombins - agonists | Chondroitin Sulfates - administration & dosage | Hirudins - adverse effects | Fibrinolytic Agents - administration & dosage | Peptide Fragments - adverse effects | Thrombosis - drug therapy | Heparin, Low-Molecular-Weight - administration & dosage | Infusions, Intravenous | Practice Guidelines as Topic | Antithrombotic Therapy and Prevention of Thrombosis, 9th Ed | American College of Chest Physician Evidence-Based Clinical Practice Guidelines Online Only
Journal Article
Journal Article
CHEST, ISSN 0012-3692, 06/2009, Volume 135, Issue 6, pp. 1651 - 1664
Thrombocytopenia following heparin administration can be associated with in immune reaction, now referred to as heparin-induced thrombocytopenia (HIT). HIT is... 
PERCUTANEOUS CORONARY INTERVENTION | RECOMBINANT HIRUDIN | FACTOR 4/HEPARIN ANTIBODIES | LINKED-IMMUNOSORBENT-ASSAY | RESPIRATORY SYSTEM | CARDIAC-SURGERY | MOLECULAR-WEIGHT HEPARIN | PLATELET-AGGREGATION TEST | CARDIOPULMONARY BYPASS | ARGATROBAN ANTICOAGULATION | UNFRACTIONATED HEPARIN | CRITICAL CARE MEDICINE | Heparitin Sulfate - adverse effects | Prognosis | Humans | Heparin - therapeutic use | Male | Recombinant Proteins - adverse effects | Heparin - adverse effects | Hirudins - administration & dosage | Monitoring, Physiologic | Thrombocytopenia - drug therapy | Chondroitin Sulfates - adverse effects | Time Factors | Heparitin Sulfate - administration & dosage | Platelet Aggregation Inhibitors - administration & dosage | Female | Thrombosis - prevention & control | Platelet Aggregation Inhibitors - adverse effects | Severity of Illness Index | Dermatan Sulfate - administration & dosage | Dermatan Sulfate - adverse effects | Peptide Fragments - administration & dosage | Risk Factors | Safety Management | Anticoagulants - therapeutic use | Survival Rate | Thrombocytopenia - chemically induced | Anticoagulants - adverse effects | Recombinant Proteins - administration & dosage | Randomized Controlled Trials as Topic | Chondroitin Sulfates - administration & dosage | Platelet Count | Hirudins - adverse effects | Pipecolic Acids | Thrombocytopenia - diagnosis | Peptide Fragments - adverse effects | Thrombosis - drug therapy | Index Medicus | Abridged Index Medicus
Journal Article
Intensive Care Medicine, ISSN 0342-4642, 08/2009, Volume 35, Issue 8, pp. 1449 - 1453
Journal Article
Advanced Healthcare Materials, ISSN 2192-2640, 11/2016, Volume 5, Issue 22, pp. 2922 - 2930
Journal Article
Journal Article
Cell death & disease, ISSN 2041-4889, 06/2017, Volume 8, Issue 6, pp. e2902 - e2902
Stimulating bone formation is an important challenge for bone anabolism in osteoporotic patients or to repair bone defects. The osteogenic properties of matrix... 
MAINTENANCE | FINE-STRUCTURE | ANGIOGENESIS | OSTEOCLAST FORMATION | SYNDECAN-2 | OSTEOGENESIS | DIFFERENTIATION | EXPRESSION | PROMOTES | BINDING | CELL BIOLOGY | Glycosaminoglycans - administration & dosage | Mesenchymal Stromal Cells - drug effects | Apoptosis - drug effects | Humans | Osteoblasts - drug effects | Osteogenesis - drug effects | Bone Resorption - drug therapy | Gene Expression Regulation, Developmental - drug effects | Mice, Transgenic | RANK Ligand | Bone Remodeling - drug effects | Animals | Wnt Signaling Pathway - drug effects | Bone Resorption - genetics | Cell Differentiation - drug effects | Heparitin Sulfate - administration & dosage | Bone Resorption - pathology | Syndecan-2 - genetics | Bone Marrow Cells - drug effects | Mice | Bone Remodeling - genetics | Osteogenesis - genetics | Heparan sulfate | Osteoprogenitor cells | NF-κB protein | Transcription factors | Glycosaminoglycans | Mesenchyme | Glycogen | Bone remodelling | Transgenic mice | Glycogen synthase kinase 3 | Lymphocytes T | Glial stem cells | Bone resorption | Signal transduction | β-catenin | Bone growth | Bone mass | Osteoblastogenesis | Transgenic animals | Rodents | Bone marrow | Ligands | Osteogenesis | Apoptosis | Bone Resorption | Heparitin Sulfate | Neurons and Cognition | Psychology and behavior | Neurobiology | Osteoblasts | Life Sciences | Bone Marrow Cells | Mesenchymal Stromal Cells | Gene Expression Regulation, Developmental | Cognitive Sciences | Cell Differentiation | Bone Remodeling | Syndecan-2 | Wnt Signaling Pathway
Journal Article
Journal Article
Molecular Pharmaceutics, ISSN 1543-8384, 02/2018, Volume 15, Issue 2, pp. 602 - 608
Journal Article
Journal of Drugs in Dermatology, ISSN 1545-9616, 07/2015, Volume 14, Issue 7, pp. 669 - 674
Heparan sulfate is an essential glycosaminoglycan that plays important roles in development, homeostasis, and disease. As a group, the glycosaminoglycans... 
Heparitin Sulfate - administration & dosage | Skin - radiation effects | Dermatologic Agents - administration & dosage | Humans | Skin Aging - drug effects | Dermatologic Agents - therapeutic use | Administration, Cutaneous | Heparitin Sulfate - therapeutic use | Skin - drug effects
Journal Article